Skip to main content

Perennial Allergic Rhinitis

25
Pipeline Programs
15
Companies
20
Clinical Trials
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
10
13
Early DiscoveryClinical DevelopmentMarket

On Market (6)

Approved therapies currently available

ALVESCOApproved
ciclesonide
Unknown Company
inhalation2008
35M Part D
OMNARISApproved
ciclesonide
Unknown Company
nasal2006
923K Part D
ZETONNAApproved
ciclesonide
Unknown Company
nasal2012
323K Part D
AstraZeneca
PULMICORTApproved
budesonide
AstraZeneca
inhalation1997
222K Part D
AstraZeneca
PULMICORT RESPULESApproved
budesonide
AstraZeneca
Corticosteroid [EPC]inhalation2000
AstraZeneca
RHINOCORTApproved
budesonide
AstraZeneca
nasal1994

Competitive Landscape

14 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
3
1
BudesonidePhase 41 trial
CiclesonidePhase 31 trial
CiclesonidePhase 31 trial
CiclesonidePhase 31 trial
Active Trials
NCT00163488Completed106Est. Aug 2005
NCT00163514Completed636Est. Jul 2005
NCT00163501Completed600Est. Apr 2005
+1 more trials
MSD
MSDIreland - Ballydine
3 programs
1
2
loratadinePhase 4
montelukastPhase 4
INS37217 Nasal SprayPhase 2
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
1
2
loratadinePhase 41 trial
montelukastPhase 41 trial
INS37217 Nasal SprayPhase 21 trial
Active Trials
NCT00210015Completed630Est. Apr 2003
NCT00730912Completed261Est. Dec 2008
NCT00590772Completed31Est. Jan 2009
Alcon
AlconFORT WORTH, TX
2 programs
1
1
Olopatadine hydrochloride 0.6% nasal sprayPhase 41 trial
Olopatadine 0.6% nasal sprayPhase 31 trial
Active Trials
NCT00578331Completed890Est. Jan 2008
NCT00789555Completed1,260Est. Jan 2011
MedInvent
MedInventUK - Gosport
1 program
1
BudesonidePhase 41 trial
Active Trials
NCT01270256Completed41Est. Aug 2012
Hanmi Pharmaceutical
2 programs
2
HCP1102Phase 31 trial
Montelukast + LevocetirizinePhase 31 trial
Active Trials
NCT04324918Completed174Est. Jun 2019
NCT01640535Completed283Est. Feb 2013
Hanlim Pharm
Hanlim PharmKorea - Seoul
2 programs
2
HL151Phase 31 trial
mometasone furoate plus azelastine HClPhase 31 trial
Active Trials
NCT03655210Completed272Est. Oct 2017
NCT01470053Completed347Est. Nov 2012
Ache Laboratorios Farmaceuticos
1 program
1
CM9241GRUPhase 31 trial
Active Trials
NCT06577077Not Yet Recruiting432Est. Aug 2025
EMS
EMSBrazil - Hortolândia
1 program
1
Cloratadd-DPhase 31 trial
Active Trials
NCT01228630Completed156Est. May 2012
Merck & Co.
Merck & Co.RAHWAY, NJ
2 programs
INS37217 Nasal SprayPHASE_2
loratadinePHASE_4
UCB Pharma
UCB PharmaBelgium - Brussels
2 programs
LevocetirizinePHASE_41 trial
levocetirizinePHASE_41 trial
Active Trials
NCT00439712Completed60Est. May 2007
NCT00894231Completed30Est. Aug 2009
Medica Corp
Medica CorpMA - Bedford
1 program
Treatment AN/A1 trial
Active Trials
NCT05122143Completed37Est. Apr 2022
Altamira Therapeutics
Altamira TherapeuticsBermuda - Hamilton
1 program
Treatment AN/A
Faes Farma
Faes FarmaSpain - Leioa
1 program
BilastinePHASE_31 trial
Active Trials
NCT01127620Completed650Est. Nov 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MedInventBudesonide
UCB Pharmalevocetirizine
AlconOlopatadine hydrochloride 0.6% nasal spray
Sharp Therapeuticsloratadine
UCB PharmaLevocetirizine
Sharp Therapeuticsmontelukast
AstraZenecaBudesonide
Ache Laboratorios FarmaceuticosCM9241GRU
Hanmi PharmaceuticalHCP1102
Hanlim PharmHL151
Hanmi PharmaceuticalMontelukast + Levocetirizine
EMSCloratadd-D
Hanlim Pharmmometasone furoate plus azelastine HCl
AlconOlopatadine 0.6% nasal spray
AstraZenecaCiclesonide

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 7,105 patients across 20 trials

NCT01270256MedInventBudesonide

NasoNeb Delivery of an Intranasal Steroid

Start: Jan 2011Est. completion: Aug 201241 patients
Phase 4Completed
NCT00894231UCB Pharmalevocetirizine

Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis

Start: Jan 2009Est. completion: Aug 200930 patients
Phase 4Completed
NCT00789555AlconOlopatadine hydrochloride 0.6% nasal spray

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

Start: Nov 2008Est. completion: Jan 20111,260 patients
Phase 4Completed
NCT00730912Sharp Therapeuticsloratadine

Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)

Start: Jun 2008Est. completion: Dec 2008261 patients
Phase 4Completed
NCT00439712UCB PharmaLevocetirizine

Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis

Start: Feb 2007Est. completion: May 200760 patients
Phase 4Completed
NCT00590772Sharp Therapeuticsmontelukast

The Role of Montelukast in Rhinitis and Sleep

Start: May 2003Est. completion: Jan 200931 patients
Phase 4Completed
NCT00641212AstraZenecaBudesonide

Children, Perennial Allergic Rhinitis (PAR), l-t Growth

Start: Jan 2000Est. completion: Apr 2003209 patients
Phase 4Completed
NCT06577077Ache Laboratorios FarmaceuticosCM9241GRU

Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis

Start: Sep 2024Est. completion: Aug 2025432 patients
Phase 3Not Yet Recruiting
NCT04324918Hanmi PharmaceuticalHCP1102

Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis

Start: Oct 2018Est. completion: Jun 2019174 patients
Phase 3Completed
NCT03655210Hanlim PharmHL151

To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

Start: Feb 2017Est. completion: Oct 2017272 patients
Phase 3Completed
NCT01640535Hanmi PharmaceuticalMontelukast + Levocetirizine

Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients

Start: Jun 2012Est. completion: Feb 2013283 patients
Phase 3Completed
NCT01228630EMSCloratadd-D

Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.

Start: Aug 2011Est. completion: May 2012156 patients
Phase 3Completed
NCT01470053Hanlim Pharmmometasone furoate plus azelastine HCl

Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis

Start: Mar 2011Est. completion: Nov 2012347 patients
Phase 3Completed
NCT00578331AlconOlopatadine 0.6% nasal spray

Safety Study of Olopatadine Nasal Spray

Start: Dec 2006Est. completion: Jan 2008890 patients
Phase 3Completed
NCT00163488AstraZenecaCiclesonide

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

Start: Jan 2005Est. completion: Aug 2005106 patients
Phase 3Completed
NCT00163514AstraZenecaCiclesonide

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

Start: May 2004Est. completion: Jul 2005636 patients
Phase 3Completed
NCT01127620Faes FarmaBilastine

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

Start: May 2004Est. completion: Nov 2006650 patients
Phase 3Completed
NCT00163501AstraZenecaCiclesonide

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

Start: Dec 2003Est. completion: Apr 2005600 patients
Phase 3Completed
NCT00210015Sharp TherapeuticsINS37217 Nasal Spray

A Study in Subjects With Perennial Allergic Rhinitis

Start: Dec 2002Est. completion: Apr 2003630 patients
Phase 2Completed
NCT05122143Medica CorpTreatment A

Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

Start: Nov 2021Est. completion: Apr 202237 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

10 late-stage (Phase 3) programs, potential near-term approvals
15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.